The Sézary syndrome treatment market — addressing an aggressive, leukemic variant of cutaneous T-cell lymphoma (CTCL) affecting fewer than 5% of all CTCL cases — is expanding at a genuinely fast pace as targeted monoclonal antibody therapy reshapes treatment options for a historically difficult-to-treat cancer, with the market valued at approximately USD 925.66 million in...